Alterity Therapeutics Limited chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 0.00
Dividend & YieldN/A$ (N/A)
Beta 1.05
Market capitalization 36.1M
Operating cash flow -18.67M
ESG Scores unknown

Company description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-06-30 2019-06-30 2020-06-30 2021-06-30
Change To Liabilities 1.16M 662.93k -648.57k 432.9k
Total Cashflows From Investing Activities -18.42k -7.02k -16.74k -10.47k
Net Borrowings -89.24k -89.24k -89.24k -58.29k
Total Cash From Financing Activities -107.68k 12.72M 3.98M 36.69M
Change To Operating Activities -89.88k -317.78k 68.64k -624.03k
Issuance Of Stock 13.08M 13.08M 4.36M 39.24M
Net Income -8.27M -12.34M -13.46M -15.31M
Change In Cash -6.65M -835.65k -5.2M 18.92M
Effect Of Exchange Rate -278.12k 403.88k 262.98k -426.78k
Total Cash From Operating Activities -6.25M -13.95M -9.43M -17.33M
Depreciation 21.8k 29.7k 112.43k 75.37k
Change To Account Receivables -116.84k -1.68M 4.77M -4.22M
Other Cashflows From Financing Activities -107.68k -362.32k -292.77k -2.49M
Change To Netincome 1.04M -314.74k -274.99k 2.31M
Capital Expenditures -62.41k -7.02k -16.74k -10.47k

Income Statement 2018-06-30 2019-06-30 2020-06-30 2021-06-30
Research Development 6.7M 12.98M 10.1M 12.28M
Income Before Tax -8.27M -12.34M -13.46M -15.31M
Net Income -8.27M -12.34M -13.46M -15.31M
Selling General Administrative 4.34M 4.31M 3.45M 7.94M
Gross Profit 2.9M 4.63M -352.92k 3.98M
Ebit -8.2M -12.8M -13.93M -16.18M
Operating Income -8.2M -12.8M -13.93M -16.18M
Interest Expense
Income Tax Expense
Total Revenue 3.13M 4.95M 4.34M
Cost Of Revenue 224.58k 322.1k 352.92k 360.03k
Total Other Income ExpenseNet -69.69k 457.6k 472.9k 869.19k
Net Income From Continuing Ops -8.27M -12.34M -13.46M -15.31M
Net Income Applicable To Common Shares -8.27M -12.34M -13.46M -15.31M

Balance Sheet Statement 2018-06-30 2019-06-30 2020-06-30 2021-06-30
Total Liabilities 2.64M 3.36M 2.76M 3.12M
Total Stockholder Equity 16.08M 16.55M 7.15M 30.47M
Other Current Liabilities 11.19k 11.72k 10.96k 33.84k
Total Assets 18.73M 19.91M 9.91M 33.59M
Common Stock 143.91M 156.63M 160.7M 197.45M
Other Current Assets 9.8k 10.03k 10.25k 9.36k
Retained Earnings -129.58M -141.24M -154.42M -169.73M
Treasury Stock 1.75M 1.16M 866.12k 2.75M
Cash 15.24M 14.4M 9.2M 28.12M
Total Current Liabilities 2.64M 3.32M 2.71M 3.07M
Other Stockholder Equity 1.75M 1.16M 866.12k 2.75M
Property, Plant, and Equipment 71.42k 48.75k 71.37k 96.81k
Total Current Assets 18.65M 19.86M 9.84M 33.49M
Net Tangible Assets 16.08M 16.55M 7.15M 30.47M
Net Receivables 3.15M 4.83M 61.32k 4.28M
Accounts Payable 1.33M 1.69M 954.03k 1.45M


Insider Transactions

Here are the insider transactions of stock shares related to Alterity Therapeutics Limited:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Mihaly (George William)D2019-04-08Former226.67k
Angus (Dianne)D2018-06-30Former146.13k
Kempler (Geoffrey Paul)Purchase at price 0.19 per share.D2015-06-01Chief Executive Officer200k
Angus (Dianne)D2014-06-30Chief Operating Officer46.13k
Kempler (Geoffrey Paul)Purchase at price 0.17 per share.D2012-05-01Chairman of the Board156k
Kempler (Geoffrey Paul)Purchase at price 0.18 per share.D2012-01-04Chairman of the Board600k
Angus (Dianne)D2011-06-30Chief Operating Officer150k
Marks (Paul)I2011-01-04Former8.59M
Angus (Dianne)D2008-06-30Chief Operating Officer250k
Meltzer (Brian Derek)D2008-06-30Director (Independent)167.82k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Alterity Therapeutics Limited. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Alterity Therapeutics Limited

Here is the result of two systematic investment strategies applied to Alterity Therapeutics Limited. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Alterity Therapeutics Limited

The following chart shows the equity curve of the two systematic investment strategies applied to Alterity Therapeutics Limited:

Alterity Therapeutics Limited automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 13.96% on the backtest period.

Performance at glance

Performance

13.96 %

Latent gain

348.89 $

Invested capital

2499.97 $

Annualized return

3.01 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Alterity Therapeutics Limited

This is the result of two momentum investment strategies applied to Alterity Therapeutics Limited. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Alterity Therapeutics Limited

The following chart shows all the entries opened by the momentum investment system on Alterity Therapeutics Limited:

Alterity Therapeutics Limited momentum entries
  • The first momentum investment strategy would give 26.1% of return on Alterity Therapeutics Limited. That represents 1435.49$ of latent gain with 5499.97$ of employed capital.
  • The second momentum investment strategy would give 40.54% of return on Alterity Therapeutics Limited. That represents 1925.53$ of latent gain with 4749.99$ of employed capital.
Performance at glance (1Q Momentum)

Performance

26.1 %

Latent gain

1435.49 $

Invested capital

5499.97 $

Annualized return

66.05 %
Performance at glance (2Q Momentum)

Performance

40.54 %

Latent gain

1925.53 $

Invested capital

4749.99 $

Annualized return

9.75 %

Momentum equity curve on Alterity Therapeutics Limited

The following chart shows the equity curve of the two momentum strategies applied to Alterity Therapeutics Limited:

Alterity Therapeutics Limited momentum equity

Note: the dividends potentially given by Alterity Therapeutics Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Alterity Therapeutics Limited

The following chart shows the employed capital evolution of the two momentum strategies on Alterity Therapeutics Limited since the beginning:

Alterity Therapeutics Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Alterity Therapeutics Limited

Buy the dip entry openings on Alterity Therapeutics Limited

Alterity Therapeutics Limited

The performance achieved by the robo-advisor on Alterity Therapeutics Limited is 174.36%. That represents 1307.7$ of latent gain with 750.01$ of employed capital. The following chart shows Alterity Therapeutics Limited stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Alterity Therapeutics Limited, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

174.36 %

Latent gain

1307.7 $

Invested capital

750.01 $

Annualized return

66.05 %

Equity curve of the strategy applied to Alterity Therapeutics Limited

The following chart shows the result of the investment strategy applied to Alterity Therapeutics Limited:

Alterity Therapeutics Limited

Note: the dividends potentially given by Alterity Therapeutics Limited are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Alterity Therapeutics Limited

The following chart shows the employed capital evolution since the beginning of the investment strategy on Alterity Therapeutics Limited:

Alterity Therapeutics Limited

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Alterity Therapeutics Limited

In this section, I will compare the three previous investment strategies applied to Alterity Therapeutics Limited.

Equity curve comparison on Alterity Therapeutics Limited

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Alterity Therapeutics Limited investment strategy comparison

Employed capital comparison on Alterity Therapeutics Limited

Alterity Therapeutics Limited investment comparison

Performance comparison on Alterity Therapeutics Limited

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 13.96% 348.89$ 2499.97$ 3.01%
Momentum 1 quarter 26.1% 1435.49$ 5499.97$ 5.93%
Momentum 2 quarters 40.54% 1925.53$ 4749.99$ 9.75%
Non-directional 174.36% 1307.7$ 750.01$ 66.05%
Annualized return comparison

Automatic investment

3.01 %

Momentum 1Q

9.75 %

Momentum 2Q

9.75 %

Non-directional

66.05 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Alterity Therapeutics Limited:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between Alterity Therapeutics Limited and the other stocks. There may be false positives or some missing correlated stocks. If the price of Alterity Therapeutics Limited does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Alterity Therapeutics Limited
Country Australia
City Melbourne
Address 460 Bourke Street
Phone 61 3 9349 4906
Website alteritytherapeutics.com
FullTime employees 11
Industry Biotechnology
Sector Healthcare
Exchange XASX
Ticker ATH.XASX
Market www2.asx.com.au

Alterity Therapeutics Limited ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown